Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward looking statements for purposes of the safe harbor provisions of the Private S

Program Summary Drug Design: Both targets clinically validated In Vitro Assays: Potent small molecules against both targets 2 to 20x more potent in antiproliferation apoptosis assays compared to a combination of EGFRi/Target Ai prototype compounds Broad activity against wide range of cancer types (23 cell lines tested) Strong inhibition in EGFRi and/or target Ai insensitive or resistant tumor cell lines PD studies: Single dose administration inhibits targeted pathways, induces anti proliferative and apoptosis effects in tumors in vivo Efficacy studies: Efficacious against diverse cancer types such as pancreatic, colon, prostate, NSCLC; including tumor cell lines resistant to EGFRi Early safety assessment: No remarkable findings in 3 week efficacy studies up to 60 mg/kg daily Well tolerated in non GLP 14 day TK toxicity study in rats; histology in progress Selectivity safety panel profile: no major concerns identified Strong IP position

Preliminary PD/efficacy in primary human tumor xenografts Efficacy studies in pancreatic, colon, prostate, additional NSCLC, and other cancers Non GLP 14 day repeat dose tox study in rats 22 Curis, Inc. Curis EGFR/Target Program Intellectual Property Strategy Omnibus application (generically claims A+B compounds; in this case, B is EGFR) Claims single compounds having at least two pharmacophores covalently bound via a linker moiety where each pharmacophore binds to a separate therapeutic target Species application filed claiming a class of compounds having an EGFRi pharmacophore covalently linked to pharmacophore A All applications filed on the same date to avoid prior art issues Patentable novelty relies on the structural novelty of the core therapeutic pharmacophore B covalently bound to pharmacophore A , the combination not being disclosed in third party IP filings We believe that the patentable novelty of Curis MTI compounds will also provide freedom to operate for the compounds per se Analysis is ongoing and will be updated as we approach lead selection 23 Curis, Inc.

CUR MTI 1 Reduces Tumor Cell Proliferation in a Model of NSCLC by Day 3 CUR MTI 1 Vehicle Control 21 Curis, Inc. Summary of Additional Data Available Under Confidentiality In vitro Metabolism in hepatocytes of different species Receptor, enzyme, kinase panel profiling In vivo PK in three species Dose dependent PD, PK PD relationship, downstream effector biomarkers, etc.

Animals were treated with CUR MTI 1 (15, 30 or 60 mg/kg) or vehicle once daily on days indicated by 18 Curis, Inc. CUR MTI 1 Inhibits EGFR Target Activity in a Model of NSCLC by 3 Day Treatment Vehicle Control CUR MTI 1 19 Curis, Inc. CUR MTI 1 Induces Apoptosis in a Model of NSCLC by 3 Day Treatment Vehicle Control CUR MTI 1 area of cell death 20 Curis, Inc.

Animals were treated with compound (15, 30 or 60 mg/kg) or vehicle once daily on days indicated by 80 90 100 110 120 0 3 6 9 12 15 18 21 Days Vehicle 15 mg/kg 30 mg/kg 60 mg/kg 50 100 150 200 250 300 350 400 450 0 3 6 9 12 15 18 21 Days Vehicle 15 mg/kg 30 mg/kg 60 mg/kg 17 Curis, Inc. Comparison of Anti Tumor Activity of CUR MTI 1 and Prototype EGFRi in H358 NSCLC Xenograft Model Animals were treated for once daily for 14 days with erlotinib (100 mg/kg qd) or vehicle control (Cancer Res 65: 9457, 2005) 50 100 150 200 250 300 0 3 6 9 12 15 18 21 24 27 Day Vehicle 15 mg/kg 30 mg/kg 60 mg/kg Pre treatment tumor size 84+23 mm ³ .

CUR MTI 1 Is Efficacious in A431 Epidermoid Tumor Xenograft Model Pre treatment tumor size is 156+57 mm ³ 100 200 300 400 500 600 700 0 3 6 9 12 15 18 21 24 Days of Treatment 48 mg/kg 24 mg/kg 12 mg/kg 6 mg/kg Vehicle 80 90 100 110 120 0 3 6 9 12 15 18 21 24 Days of Treatment 48 mg/kg 24 mg/kg 12 mg/kg 6 mg/kg Vehicle 16 Curis, Inc. CUR MTI 1 Is Efficacious in H292 NSCLC Xenograft Model Pre treatment tumor size is 116.3+23.2 mm 3.

Cur MTI 1 Displays Potent Induction of Apoptosis In Cancer Cell Lines Cur MTI 11 induces ~4 to 11x more cell apoptosis as measured by increased caspase 3 7 activity EGFRi prototype drug is inactive at a concentration 20 M HCT 116 (Colon): 24 hrs 4X Cur MTI 1 (0.17 uM) Target Ai (2.18 uM) EGFRi ( 20 uM ) Combined (0.67 uM) SKBr3 (Breast): 24 hrs 11X Cur MTI 1 (0.92 uM) Target Ai (10.1 uM) EGFRi ( 20 uM ) Combined (10.0 uM) 15 Curis, Inc.

Cur MTI 1 Improves Anti Proliferative Activity Against Other Major Cancer Cell Lines (IC 50 in uM) Cell lines from five major types of cancer (lung, breast, prostate, colon, and pancreas) responded better than a combination of EGFRi and Target Ai Cur MTI 1 highly active against breast cancer cell lines (10x 20x) Tumor Line Tumor Type Target Ai EGFRi Target Ai/EGFRi Combined Cur MTI 1 Improvement In Potency MDA MB 231 Breast adenocarcinoma 0.28 27.39 0.12 0.006 20x HCT116 Colon cancer 0.73 11.74 0.60 0.04/0.23 3 14x MCF 7 Breast adenocarcinoma 0.73 34.00 0.67 0.05 13x MDA MB 468 Breast adenocarcinoma 1.58 3.50 0.56 0.04 13x SKBr3 Breast carcinoma 4.60 20 3.15 0.32 10x PC 3 Prostate adenocarcinoma 4.80 20 3.00 0.61 5x Caki 1 Renal carcinoma 0.11 0.06 0.12 0.04 3x A431 Epidermoid carcinoma 1.00 2.33 0.54 0.23 2x 22RV1 Prostate carcinoma 0.09 0.17 0.06 0.07 1x 14 Curis, Inc.

Cur MTI 1 Improves Anti Proliferative Activity Against Pancreatic Cancer Cell Lines (IC 50 in uM) Pancreatic tumor cells are not sensitive to EGFR inhibition; Cur MTI 1 IC 50 values range from 0.27 0.95 uM against 6 major pancreatic carcinoma cell lines Cur MTI 1 is more potent than a combination of both prototype drugs Tumor Line Target Ai EGFRi Target Ai/EGFRi Combined Cur MTI 1 Improvement In Potency HPAC 25.1 25.0 9.9 0.95 10x MiaPaCA 1.7 15.8 1.7 0.29 6x CFPAC 7.7 14.9 3.2 0.56 6x Capan1 7.3 26.9 4.4 0.80 6x PANC 4.3 21.6 3.4 0.66 5x BxPC3 2.7 7.6 1.0 0.27 4x 13 Curis, Inc.

Cur MTI 1 Improves Anti Proliferative Activity Against Non Small Cell Lung Cancer Cell Lines (IC 50 in uM) Proliferation is inhibited in both EGFRi sensitive and resistant NSCLC cell lines Cur MTI 1 is more potent than a combination of both prototype drugs Tumor Line Tumor Type Target Ai EGFRi Target Ai/EGFRi Combined Cur MTI 1 Improvement In Potency H1975 L858R + T790M 4.7 10 4.0 0.5 9x H1703 Squamous, WT 4.7 9.0 1.8 0.2 8x HCC827 Adeno, E19Del, amplified 1.8 7.5 2.3 0.6 4x H358 Adeno, WT, amplified 2.5 6 7 1.1 0.4 3x H292 Mucoepidermoid, WT 1.1 1.3 0.6 0.2 3x H460 Large cell, WT 1.7 8.2 1.4 0.7 2x H2122 Adeno, WT 7.5 1.0 0.4 0.3 1x A549 Adeno, WT 3.5 16.7 ND 2.1 ND 12 Curis, Inc.

Curis Multi Target Inhibitors Are More Potent Than Prototype Drugs in In Vitro Assays Target A Enzyme Assay 5 10 fold more potent EGFR Enzyme Assay 15 20 fold more potent EGFR Enzyme Assay Target A Enzyme Assay A 10 Curis, Inc. Curis MTIs Display Dose Dependent Inhibition of Both Targets in A431 cells EGF Control EGFR p EGFR EGFR p EGFR 1h 24h EGFRi (uM) CUR MTI 1 + + + + + 10 0.1 1 10 5h Target A readout Loading control Control Target A readout Loading control CUR MTI 1 10 1 10 1h Control Target Ai CUR MTI 1 10 (uM) EGFRi (uM) 0.1 0.1 1 10 11 Curis, Inc.

In vivo biology assays Curis InforSense Drug Development Web Portal Project Curis China Shanghai 8 Curis, Inc. EGFR and Target A Multi Target Inhibitor Program EGFR signaling can lead to tumor growth and development via multiple processes, including enhanced cellular proliferation, survival, and metastasis Many inhibitors of the EGFR have been developed, targeting either the extracellular receptor domain with antibodies or the intracellular tyrosine kinase binding domain with small molecules Target A is considered to be a promising target in drug development for cancer therapy and has been clinically validated Curis is developing single small molecule inhibitors which target both EGFR and Target A 9 Curis, Inc.

Curis Drug Development Process Curis US Cambridge, MA 1. Design compound structures 2. Submits structure for synthesis 3. Chemist synthesizes compound 4. Performs analytical analysis 5. Enters yield, purity, analytical results into database 6. Compound registered in Curis database shipped to Curis US Synthetic Chemistry DB 7. In vitro biology assays Curis Compound DB In vitro biology DB In vivo biology DB 8.

Curis Approach to Drug Discovery US operations Scientific leadership, inventorship core competencies Compound design, in vitro assays, PK/PD, animal cancer models performed in US tightly integrated for rapid progress Close coordination between Curis R D and legal groups as each program progresses creating strong IP portfolio China based CRO used for medicinal chemistry synthesis Overseen by Curis chemists in US Takes advantage of time difference (24/7 research operations) Substantial enhancement of productivity Web portal based database and tracking system being developed 7 Curis, Inc.

Drug Resist Updat. 8:183, 2005; Budillon A et al. Curr Drug Targets 6:241, 2005 Daub H et al. Nat Rev Drug Disc 3 1001 2004; Daub H et al. Nat Rev Drug Dis 3:1001, 2004 5 Curis, Inc. Commercial Opportunity Sales of already marketed targeted cancer drugs expected to grow to $25.2 billion by 2015 (up from $7.5 billion in 2005) Targeted therapies expected to constitute 55% of top 20 oncology drugs by 2015 Several multi targeted agents are expected to be in the top 20 by 2015: Nexavar, Sutent, Sprycel These market forecasts are in addition to already established, single agent blockbuster drugs (Avastin, Tarceva) Datamonitor Report Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies More drugs on the market, more targets in the pipeline . 10/10/06 6 Curis, Inc.

Rationale for Designing Multi Target Inhibitor Drugs Against Cancer Low risk expected Validated molecular targets Established clinical path Reduced development costs, timelines anticipated Potential for accelerated market acceptance, long market exclusivity May be more efficacious Heterogeneity of tumor cells (multiple mutated pathways) Lower effective doses (synergism), fewer dose limiting toxicities Prevention of drug resistance, efficacy in resistant patients Broxterman HJ et al.

Curis Aims to Develop Next Generation of Targeted Anticancer Drugs Targeted anticancer therapy: to target pathways and proteins involved in malignant transformation Selective kinase inhibitors are clinically efficacious and much less toxic than chemotherapy Newly approved multiple kinase inhibitors are more broadly effective Curis expects that the next generation of targeted anticancer drugs, by engaging more key targets, will be more efficacious and work against multiple cancers 4 Curis, Inc.

Outline Novel small molecules comprise two covalently bound pharmacophores, one targeting EGFR and the other inhibiting a second, validated cancer target (Target A) Rationale for multi target inhibitor drugs seeking to create Best in Class drugs Curis approach to cancer drug discovery In vitro potency In vivo efficacy Summary of additional in vivo data Intellectual property summary Program summary 3 Curis, Inc.

The forward looking statements included in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. While we may elect to update these forward looking statements in the future, we specifically disclaim any obligation to do so. These forward looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation. 2 Curis, Inc.

Actual results may differ materially from those indicated by these forward looking statements as a result of various important factors, including risks relating to: both our and our collaborators ability to successfully research, obtain regulatory approvals for, develop and commercialize products based upon our technologies; our ability to obtain and maintain proprietary protection for our technologies and product candidates, including our multi target inhibitors; competitive pressures; our ability to maintain strategic collaborations, including with Genentech, Ortho Biotech and Wyeth; our ability to successfully execute on, and receive favorable results from, our proprietary drug development efforts; our ability to raise additional funds to finance our operations; and those factors described in our Annual Report on Form 10 K for the year ended December 31, 2006, and other reports that we file with SEC.

1 Non Confidential Presentation March 8, 2007 Multi Target Inhibiting Small Molecules Exhibit 99.1 Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.